« Back to Record
Citation APA

Boothman, I., Clayton, L. M. S., McCormack, M., Driscoll, A. M., Stevelink, R., Moloney, P., Krause, R., Kunz, W. W., Diehl, S., O'Brien, T., Sills, G., de Haan, G. J., Zara, F., Koeleman, B., Depondt, C., Marson, A. G., Stefansson, H., Stefansson, K., Craig, J., Johnson, M. R., Striano, P., Lerche, H., Furney, S., Delanty, N., Consortium EpiPGX,, Sisodiya, S. M., & Cavalleri, G. L. (2023). Testing for pharmacogenomic predictors of ppRNFL thinning in individuals exposed to vigabatrin. Frontiers in Neuroscience, 17, 1156362. doi:10.3389/fnins.2023.1156362


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/364695

Boothman, I., Clayton, L. M. S., McCormack, M., Driscoll, A. M., Stevelink, R., Moloney, P., Krause, R., Kunz, W. W., Diehl, S., O'Brien, T., Sills, G., de Haan, G. J., Zara, F., Koeleman, B., Depondt, C., Marson, A. G., Stefansson, H., Stefansson, K., Craig, J., Johnson, M. R., Striano, P., Lerche, H., Furney, S., Delanty, N., Consortium EpiPGX,, Sisodiya, S. M., & Cavalleri, G. L. (2023). Testing for pharmacogenomic predictors of ppRNFL thinning in individuals exposed to vigabatrin. Frontiers in Neuroscience, 17, 1156362. doi:10.3389/fnins.2023.1156362